This study examined how host metadherin (MTDH) in hepatocytes and CD8+ T cells mediates tumor-induced immunosuppression and metabolic reprogramming through tumor-liver crosstalk, using Mtdh knockout mouse models across tumor growth and metastasis settings.
MTDH loss restored hepatic PPARα-mediated lipid oxidation (suppressed via tumor-derived EVP → Kupffer cell → TNF-α/TGF-β → NF-κB axis), reduced systemic lipid levels, boosted CD8+ T cell mitochondrial function, and suppressed tumor growth and metastasis; genetic or pharmacological MTDH inhibition synergized with anti-PD-1 therapy.
Findings are primarily from mouse knockout models, so clinical translatability to human cancer patients is not yet established. The specific pharmacological MTDH inhibitor used and its safety profile are not detailed in the abstract. Causal directionality of individual pathway steps (e.g., which lipid species drive CD8+ T cell reprogramming) is not fully resolved.
MTDH is a potential therapeutic target to overcome lipid-mediated immunosuppression in cancer; combining MTDH inhibition with anti-PD-1 therapy may enhance antitumor responses, though this remains preclinical. Clinicians should watch for emerging MTDH-targeting agents entering trials, especially in solid tumors with liver involvement.
